D-0703-2017 Class III Terminated

Recalled by Teva Pharmaceuticals USA — North Wales, PA

FDA drug recall D-0703-2017 was initiated by Teva Pharmaceuticals USA on Mar 28, 2017 and is designated Class III. Reason for recall: Failed Stability Specifications The recall status is terminated (terminated Oct 24, 2017). Affected quantity: 49,089 bottles.

Recall details

Product Type
Drugs
Report Date
May 17, 2017
Initiation Date
Mar 28, 2017
Termination Date
Oct 24, 2017
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
49,089 bottles

Product description

PrednisoLONE Oral Solution USP, 15 mg/5mL, alcohol content: 5%(v/v) 240 mL bottle, Rx Only, Manufactured in Canada By: CONTRACT PHARMACEUTICALS LIMITED CANADA, Ontario, Canada, L5N 6L6, Manufactured For: TEVA PHARMACEUTICALS USA, Sellersville, PA 18960, NDC 0093-6118-87

Reason for recall

Failed Stability Specifications

Distribution pattern

Nationwide

Code information

Lot # 94358; Exp. 05/17 Lot # 94920A; Exp. 07/17 Lot # 97083A; Exp. 12/17

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0703-2017
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0703-2017. Report a data issue: hello@regdatalab.com.